AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Nolan-Stevaux O, Li C, Liang L, Zhan J, Estrada J, Osgood T, Li F, Zhang H, Case R, Murawsky CM, Estes B, Moore GL, Bernett MJ, Muchhal U, Desjarlais JR, Staley BK, Stevens J, Cooke KS, Aeffner F, Thomas O, Stieglmaier J, Lee JL, Coxon A, Bailis JM.
Nolan-Stevaux O, et al. Among authors: li f, li c.
Cancer Discov. 2024 Jan 12;14(1):90-103. doi: 10.1158/2159-8290.CD-23-0984.
Cancer Discov. 2024.
PMID: 37861452